There has been much discussion about the need for Australia to increase “sovereign capability” in domestic pharmaceutical manufacturing.
Against an international backdrop this article discusses the identified supply chain risks and considers whether such an initiative is commercially feasible in the absence of significant government investment and intervention. It also looks at two key initiatives already in place designed to help mitigate the risk of medicine supply chain shortages.
Legal Notice
The contents of this publication are for reference purposes only and may not be current as at the date of accessing this publication. They do not constitute legal advice and should not be relied upon as such. Specific legal advice about your specific circumstances should always be sought separately before taking any action based on this publication.
© Herbert Smith Freehills 2024